In this article, we will look at the 14 Best Long Term Low Volatility Stocks to Buy Right Now.

Mike Wilson, Morgan Stanley CIO and chief U.S. equity strategist, appeared on CNBC’s ‘Squawk Box’ to discuss several aspects of the stock market, including the latest market trends and the state of the economy.

He stated that his differentiated view is that we have been in a rolling recession for the past 2-3 years, with a weak private economy. Now, however, we are in a rolling recovery, as according to Wilson the recession ended with the DOGE layoffs. Looking at the data closely, and as documented by the firm, there was a spike in layoffs and a low in jobs creations, which is being proved by the revisions now.

READ ALSO: 11 Best Small Cap Stocks with the Highest Upside and 9 Best Healthcare Stocks with the Highest Upside. 

Wilson further stated that the stock market is smarter than all of us, which is why it figured this trend out. The confirmation for us, according to him, is that the earnings revisions have exploded higher in a way they only do in a new economic cycle.

With these trends in view, let’s look at the best long-term low volatility stocks to buy right now.

Our Methodology 

We used Finviz to compile a list of top stocks with a 5-year revenue growth above 10% and beta below 1. We then selected the top 14 stocks with the highest number of hedge fund holders as of Q2 2025, sourcing the hedge fund sentiment data from Insider Monkey’s database. The list is sorted in ascending order of hedge fund sentiment.

Note: All data was recorded on October 20.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).

14 Best Long Term Low Volatility Stocks to Buy Right Now

14. Novo Nordisk A/S (NYSE:NVO)

5-Year Revenue Growth: 19.77%

Beta: 0.33

Number of Hedge Fund Holders: 45

Novo Nordisk A/S (NYSE:NVO) is one of the best long term low volatility stocks to buy right now. J.P. Morgan analyst Richard Vosser maintained a Buy rating on Novo Nordisk A/S (NYSE:NVO) in a report released on October 17, setting a price target of DKK500.

The rating followed Novo Nordisk’s (NYSE:NVO) announcement on October 15 that it entered into a definitive asset purchase and license agreement with Omeros Corporation for the candidate drug zaltenibart, previously known as OMS906, in clinical development for rare blood and kidney disorders.

Management reported that the terms of the agreement provide Novo Nordisk A/S (NYSE:NVO) exclusive global rights for the development and commercialization of the drug in all indications. Omeros Corporation is eligible to receive upfront and near-term milestone payments worth $340 million, up to a “total of $2.1 billion including potential development and commercial milestones, plus tiered royalties on net sales”.

Novo Nordisk A/S (NYSE:NVO) is a global healthcare company specializing in diabetes care. It develops, discovers, manufactures, and markets pharmaceutical products. Its operations are divided into two business segments: biopharmaceuticals and diabetes and obesity care. The latter segment covers GLP-1, insulin, and other protein-related products.

13. AstraZeneca PLC (NASDAQ:AZN)

5-Year Revenue Growth: 17.07%

Beta: 0.17

Number of Hedge Fund Holders: 48

AstraZeneca PLC (NASDAQ:AZN) is one of the best long term low volatility stocks to buy right now. AstraZeneca PLC (NASDAQ:AZN) received a rating update from J.P. Morgan analyst Richard Vosser on October 20, who assigned the stock a Buy rating with a £140 price target.

The rating update followed AstraZeneca PLC’s (NASDAQ:AZN) announcement of positive results from the TROPION-Breast02 Phase III trial on October 19. The results showed that AstraZeneca and Daiichi Sankyo’s Datroway (datopotamab deruxtecan) exhibited a clinically meaningful and statistically significant improvement for “the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) compared to investigator’s choice of chemotherapy as 1st-line treatment for patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) for whom immunotherapy was not an option.”

Management reported that Datroway is the first and only therapy to considerably improve the overall survival compared to chemotherapy in this patient population, showing a “highly statistically significant and clinically meaningful 43% reduction in patients’ risk of disease progression or death”.

AstraZeneca PLC (NASDAQ:AZN) is a biopharmaceutical company that explores, develops, manufactures, and commercializes prescription medicines. It supplies its products and services to specialty and primary care physicians.

12. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

5-Year Revenue Growth: 16.15%

Beta: 0.43

Number of Hedge Fund Holders: 53

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the best long term low volatility stocks to buy right now. Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on October 21 with a price target of $563.

The analyst based the optimistic rating on the company’s strong growth potential and market position, stating that Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has exhibited steady revenue growth, especially in its cystic fibrosis (CF) franchise, with products like Alyftrek and Trikafta making significant contributions.

Despite the regulatory monitoring requirements, Ahmad stated that management’s optimistic outlook for Alyftrek reflects its potential for expanded market share.

The analyst also highlighted factors reflecting promising advancements in Vertex Pharmaceuticals Incorporated’s (NASDAQ:VRTX) pipeline, such as the ongoing developments in the company’s kidney portfolio, including the initiation of the OLYMPUS trial and the FDA’s rolling review for povetacicept.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a global biotechnology company that develops medicines for rare serious diseases. Its four approved medicines treat cystic fibrosis (CF), and one approved therapy treats severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company’s product pipeline includes clinical-stage programs for various disorders, including TDT, SCD, CF, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, myotonic dystrophy type 1, and alpha-1 antitrypsin deficiency.

11. Newmont Corporation (NYSE:NEM)

5-Year Revenue Growth: 14.14%

Beta: 0.36

Number of Hedge Fund Holders: 66

Newmont Corporation (NYSE:NEM) is one of the best long term low volatility stocks to buy right now. On October 16, BofA lifted its price target on Newmont Corporation (NYSE:NEM) to $115 from $105 while keeping a Buy rating on the shares.

The firm told investors that it raised its price target for its North American precious metals coverage by an average of 16%, primarily due to the higher forecasts for gold and silver prices.

BofA added that according to the new forecasts of its commodities team, gold is anticipated to hit $5,000 per ounce and silver to reach $65 per ounce.

Newmont Corporation (NYSE:NEM) is a global producer in Canada, Mexico, the US, and several other countries. Its operations include Brucejack, Red Chris, Penasquito, Merian, Cerro Negro, Yanacocha, Boddington, Tanami, Cadia, Lihir, Ahafo, and NGM.

10. Elevance Health, Inc. (NYSE:ELV)

5-Year Revenue Growth: 10.87%

Beta: 0.59

Number of Hedge Fund Holders: 67

Elevance Health, Inc. (NYSE:ELV) is one of the best long term low volatility stocks to buy right now. Elevance Health, Inc. (NYSE:ELV) reported its fiscal Q3 2025 results on October 21, announcing $50.1 billion in operating revenue for the quarter, up 12.0% compared to the same quarter last year. Diluted EPS for the quarter reached $5.32, while adjusted diluted EPS was $6.03.

The company reaffirmed its fiscal year 2025 benefit expense ratio and adjusted diluted EPS guidance of around 90.0% and around $30.00, respectively. Elevance Health, Inc. (NYSE:ELV) also returned $3.3 billion of capital to shareholders year-to-date.

Management further reported that the operating cash flow for fiscal Q3 2025 was $4.2 billion year-to-date, or “0.8 times GAAP net income, a decrease of $0.9 billion year over year reflecting in part the Provider Settlement Agreement payment for the multi-district BCBSA litigation”. Cash and investments at the parent company come up to around $2.6 billion as of September 30, 2025.

Elevance Health, Inc. (NYSE:ELV) is a health company that operates through the following segments: Health Benefits, CarelonRx, Carelon Services, and Corporate and Other. The Health Benefits segment offers a range of health plans and services, while the CarelonRx segment manages pharmacy services. The Carelon Services segment offers various healthcare-related services by integrating behavioral, physical, pharmacy, and social services.

9. RTX Corporation (NYSE:RTX)

5-Year Revenue Growth: 11.51%

Beta: 0.65

Number of Hedge Fund Holders: 71

RTX Corporation (NYSE:RTX) is one of the best long term low volatility stocks to buy right now. RTX Corporation (NYSE:RTX) announced its fiscal Q3 2025 results on October 21, reporting sales of $22.5 billion, up 12% compared to the prior year period. GAAP EPS for the quarter reached $1.41.

Management further reported that adjusted EPS for fiscal Q3 2025 was $1.70, up 17% compared to the prior year period. Operating cash flow reached $4.6 billion, while free cash flow was $4.0 billion.

RTX Corporation (NYSE:RTX) also returned $0.9 billion of capital to shareowners, paid down $2.9 billion of debt, and completed the divestiture of Collins’ actuation and flight control business.

RTX Corporation (NYSE:RTX) is an aerospace and defense company that provides aerospace and defense services and systems to military, commercial, and government customers. The company operates through the following segments: Collins Aerospace Systems (Collins), Pratt and Whitney, Raytheon Intelligence and Space (RIS), and Raytheon Missiles and Defense (RMD).

8. ConocoPhillips (NYSE:COP)

5-Year Revenue Growth: 18.80%

Beta: 0.63

Number of Hedge Fund Holders: 72

ConocoPhillips (NYSE:COP) is one of the best long term low volatility stocks to buy right now. Susquehanna maintained a Buy rating on ConocoPhillips (NYSE:COP) on October 20 with a $110 price target, telling investors that it is updating its price targets and estimates before the Q3 earnings for its E&P coverage. The firm stated that it is reducing its Q4 WTI price assumption to $62.50 per barrel, and is maintaining its 2026 assumption at $65 per barrel.

Furthermore, ConocoPhillips (NYSE:COP) was initiated with an Equal Weight rating by Wells Fargo analyst Sam Margolin on October 16. Wells Fargo initiated coverage on the global integrated oil, refiners, and Canadian majors group, reasoning that “everyone is bearish” on oil and energy, and it is creating opportunities.

The firm is choosing stocks on the basis of return of capital direction, stating that while demand indicators are soft, US onshore activity trends are reflecting a supply counter-balance. Wells Fargo believes that relative performance in the sector is driven by return of capital direction.

ConocoPhillips (NYSE:COP) is an exploration and production company that explores, transports, produces, and markets natural gas, crude oil, and bitumen. It operates through the following geographical segments: Alaska, Lower 48, Canada, Europe, the Middle East, and North Africa, Asia Pacific, and Other International.

7. T-Mobile US, Inc. (NASDAQ:TMUS)

5-Year Revenue Growth: 10.20%

Beta: 0.58

Number of Hedge Fund Holders: 76

T-Mobile US, Inc. (NASDAQ:TMUS) is one of the best long term low volatility stocks to buy right now. On October 20, Wells Fargo analyst Eric Luebchow reiterated a Buy rating on T-Mobile US, Inc. (NASDAQ:TMUS), assigning the stock a $260 price target.

The same day, T-Mobile US, Inc. (NASDAQ:TMUS) announced the launch of “Edge Control” and “T-Platform”, new advanced network solutions redefining mission-critical connectivity for businesses.

Management reported that Edge Control “harnesses America’s only 5G Advanced network with Local Breakout to help slash latency, costs and security risk” all of which is seamlessly controlled by T-Platform, a “first-of-its-kind unified management platform for T-Mobile for Business solutions”.

The company is enhancing its Advanced Network Solutions (ANS) portfolio through capabilities “purpose-built for mission-critical operations”.

T-Mobile US, Inc. (NASDAQ:TMUS) also reported that enterprises across sports, media, and entertainment and public sector are already exploring new possibilities with Edge Control and T-Platform to enhance operations, including industry leaders such as the PGA of America, Formula 1 Heineken Las Vegas Grand Prix and the military.

T-Mobile US, Inc. (NASDAQ:TMUS) provides wireless communications services under the T-Mobile and MetroPCS brands. The company offers prepaid and postpaid wireless messaging, voice, and data services, along with wholesale wireless services.

6. Palo Alto Networks, Inc. (NASDAQ:PANW)

5-Year Revenue Growth: 22.03%

Beta: 0.97

Number of Hedge Fund Holders: 77

Palo Alto Networks, Inc. (NASDAQ:PANW) is one of the best long term low volatility stocks to buy right now. BofA lifted price target on Palo Alto Networks, Inc. (NASDAQ:PANW) to $240 from $215 on October 20, keeping a Buy rating on the shares.

The firm told investors that the cybersecurity and networking sectors are continually benefiting from strong momentum, with fundamentals across networking exhibiting healthy patterns.

It added that factors such as continued technology evolution and growing enterprise security budgets are supporting cybersecurity demand. While the firm acknowledged that valuation is a “long-term concern,” BofA anticipates sentiment to continue supporting momentum in the intermediate term, which is why it updated its price targets “accordingly”.

Palo Alto Networks, Inc. (NASDAQ:PANW) provides network security solutions to service providers, enterprises, and government entities. Its operations are divided into the following geographical segments: the United States, Israel, and Other Countries.

5. The Progressive Corporation (NYSE:PGR)

5-Year Revenue Growth: 15.21%

Beta: 0.32

Number of Hedge Fund Holders: 99

The Progressive Corporation (NYSE:PGR) is one of the best long term low volatility stocks to buy right now. Morgan Stanley analyst Bob Huang slashed the price target on The Progressive Corporation (NYSE:PGR) to $214 from $265 on October 20, downgrading the stock to Underweight from Equal Weight.

The firm told investors that it considers The Progressive Corporation’s (NYSE:PGR) bull case to be less visible when stripping out Florida, adding that the company is entering into a softer part of the pricing cycle. This is likely to result in a further compression of valuation multiples, according to the analyst. The firm added that the cyclical nature of the business suggests earnings declines in 2026 and 2027.

The Progressive Corporation (NYSE:PGR) is an insurance holding company that provides residential property insurance, personal and commercial auto insurance, and other specialty property-casualty insurance and related services. The company operates through the Personal Lines, Commercial Lines, and Property segments.

4. Alibaba Group Holding Limited (NYSE:BABA)

5-Year Revenue Growth: 12.78%

Beta: 0.17

Number of Hedge Fund Holders: 101

Alibaba Group Holding Limited (NYSE:BABA) is one of the best long term low volatility stocks to buy right now. Alibaba Group Holding Limited (NYSE:BABA) received a rating update from Barclays analyst Jiong Shao on October 21, who maintained a Buy rating on the stock with a $190 price target.

The rating update followed Alibaba Group Holding Limited’s (NYSE:BABA) announcement with Ant Group Co., Ltd. on October 17, stating that they entered into an agreement to acquire several office floors at One Causeway Bay from the Mandarin Oriental International Group for approximately HK$7.2 billion (US $925 million). The floors would be used as their Hong Kong headquarters, and the acquisition marks the largest office property transaction in Hong Kong since 2021.

Management reported that the acquisition is a strategic investment by Ant Group Co., Ltd. and Alibaba Group Holding Limited (NYSE:BABA) in “recognition of Hong Kong’s status as an international business hub and global financial center”, along with its emerging role in the development of innovative technologies.

Alibaba Group Holding Limited (NYSE:BABA) manages and provides technology infrastructure and marketing platforms. It operates through seven segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments.

3. ServiceNow, Inc. (NYSE:NOW)

5-Year Revenue Growth: 24.98%

Beta: 0.92

Number of Hedge Fund Holders: 106

ServiceNow, Inc. (NYSE:NOW) is one of the best long term low volatility stocks to buy right now. Bank of America Securities analyst Bradley Sills reiterated a bullish outlook for ServiceNow, Inc. (NYSE:NOW) on October 21, retaining the $1,200 price target.

The analyst stated that ServiceNow, Inc.’s (NYSE:NOW) core IT service management and operations categories are experiencing stable to improving demand, further supported by solid upgrades and a healthy pilot deals pipeline.

Sills also cited the rising adoption of ServiceNow, Inc.’s (NYSE:NOW) HR solutions with enterprises relying on it as a strategic interface, along with the strong deal activity in the Federal sector.

In addition, favorable currency conditions are likely to support the potential for a slight upside in Q3’s current remaining performance obligations growth, according to the analyst.

ServiceNow, Inc. (NYSE:NOW) offers an AI platform for business transformation, boosting productivity and maximizing business outcomes. Its intelligent platform, Now Platform, provides end-to-end workflow automation for digital businesses. Now Platform functions as a cloud-based solution embedded with AI and ML.

2. Thermo Fisher Scientific Inc. (NYSE:TMO)

5-Year Revenue Growth: 10.48%

Beta: 0.77

Number of Hedge Fund Holders: 117

Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the best long term low volatility stocks to buy right now. On October 20, Bank of America Securities analyst Michael Ryskin reiterated a Buy rating on Thermo Fisher Scientific Inc. (NYSE:TMO), without assigning a price target.

The rating update followed Thermo Fisher Scientific Inc.’s (NYSE:TMO) announcement on October 16 that it is planning to further expand the impact of its proven growth strategy through the use of AI with OpenAI. The collaboration is expected to enhance the speed and success of drug development, allowing customers to distribute medicines to patients faster and more cost effectively.

In its collaboration with OpenAI, Thermo Fisher Scientific Inc. (NYSE:TMO) is focusing on “accelerating scientific innovation, enhancing productivity, and reducing complexity”, embedding Open AI APIs (Application Programming Interfaces) into critical areas of its business. This includes service delivery, product development, operational efficiency, and customer engagement.

Thermo Fisher Scientific Inc. (NYSE:TMO) provides analytical instruments, reagents, equipment, software, and other services for analysis, research, diagnostics, and discovery. It operates through the Analytical Instruments, Life Sciences Solutions, Laboratory Products and Services, and Specialty Diagnostics segments.

1. Eli Lilly and Company (NYSE:LLY)

5-Year Revenue Growth: 18.34%

Beta: 0.46

Number of Hedge Fund Holders: 119

Eli Lilly and Company (NYSE:LLY) is one of the best long term low volatility stocks to buy right now. On October 17, J.P. Morgan analyst Chris Schott maintained a bullish stance on Eli Lilly and Company (NYSE:LLY), keeping his Buy rating.

The same day, Eli Lilly and Company (NYSE:LLY) announced results from the primary overall survival (OS) analysis of the Phase 3 monarchE trial, showing that “two years of adjuvant Verzenio plus endocrine therapy (ET) reduced the risk of death by 15.8% versus ET alone and resulted in sustained long-term improvements in invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS), in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), node-positive, high-risk early breast cancer”.

Management reported that the results were published in the Annals of Oncology and are being submitted to regulatory health authorities across the globe.

Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span oncology, diabetes, immunology, neuroscience, and other therapies.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.